Google News Alert for: cancer
| YM BIOSCIENCES' NIMOTUZUMAB SELECTED FOR MULTINATIONAL PHASE III ... Reuters - USA The NCCS stated that it selected nimotuzumab because of its reported preferential safety profile compared with other EGFR-targeting cancer drugs. ... See all stories on this topic |
This as-it-happens Google Alert is brought to you by Google.
Create another alert.
Manage your alerts.
No comments:
Post a Comment